RQ Bio
- Company typePrivate
- Founded2021
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
RQ Bio firmographics
Firmographics- Name
- RQ Bio
- Legal name
- RQ Biotechnology Ltd.
- Website
- https://rqbiotechnology.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
RQ Bio industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
- akta.pro secondary industry
- Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins) (HLAAAEAH)
Keywords
Where RQ Bio is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
RQ Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Licensing Royalties: RQ Bio discovers and develops antibody therapeutics, then licenses them to pharmaceutical partners for late-stage development and commercialization. The company receives milestone payments and royalties from licensees such as AstraZeneca for sipavibart (Kavigale). This model allows RQ Bio to focus on early-stage discovery while partners handle regulatory, manufacturing, and commercial execution.
- Future Product Revenue: Post-clinical development, RQ Bio may commercialize lead programme RQB01 and other pipeline assets either independently or through additional partnerships, generating revenue from product sales.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
RQ Bio product offering
Product offeringCore offering
RQ Bio discovers and develops long-acting monoclonal antibody (LAAB) therapeutics that provide passive immunity against viral infections, with lead programme RQB01 designed to deliver once-yearly protection against seasonal influenza for immunocompromised and high-risk populations. The company also developed Kavigale (sipavibart), a monoclonal antibody for COVID-19 prevention in immunocompromised individuals aged 12 and older, which was exclusively licensed to AstraZeneca. RQ Bio's therapeutic antibodies target conserved epitopes of viral proteins via a dual mechanism of action to combine potent neutralising activity with resilience to seasonal variation.
Product overview
RQ Bio is a UK-based biotechnology company developing long-acting monoclonal antibody (LAAB) therapeutics for the prevention of respiratory viral diseases. The core offering is the LAAB platform, with lead programme RQB01 for seasonal influenza prevention currently in IND-enabling studies. Additionally, RQ Bio developed Kavigale (sipavibart), a COVID-19 antibody that was licensed to AstraZeneca and received positive CHMP opinion in 2025. The company's pipeline focuses on providing passive immunity to high-risk and immunocompromised populations who cannot rely on vaccination alone.
Differentiator
Problem solved
Functional benefit
Brands
- Kavigale: Monoclonal antibody product (sipavibart) for COVID-19 prevention in immunocompromised individuals, licensed to AstraZeneca.
Products and services
- RQB01 Lead programme: a long-acting monoclonal antibody (LAAB) designed to provide potent, resilient, once-yearly protection against seasonal influenza through a dual mechanism of action targeting conserved epitopes, currently in IND-enabling studies and targeting high-risk and immunocompromised populations.
- Kavigale (sipavibart, AZD3152) Monoclonal antibody (sipavibart, formerly AZD3152) for pre-exposure prophylaxis of COVID-19 in immunocompromised individuals aged 12 years and older; discovered by RQ Bio and exclusively licensed to AstraZeneca in May 2022, receiving positive CHMP opinion in January 2025.
- Long-Acting Monoclonal Antibodies (LAABs) Platform Engineered immunity platform developing long-acting monoclonal antibodies designed to provide immediate, powerful, and long-lasting protection against severe viral diseases, particularly for populations that vaccines miss such as immunocompromised individuals, the elderly, and newborns.
Quantifiable outcome
- RQB01 in IND-enabling studies for influenza prevention
- +1 more outcomes
Companies that use RQ Bio
Customer profileSegments1 record
Ideal customer profiles2 records
RQ Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
RQ Bio partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered founding partner and strategic partner.
- University of Oxfordfounding partnerDeep collaboration with University of Oxford for antibody discovery. RQ Bio was founded by four infectious disease scientists and has ongoing research partnership. University of Oxford through Oxford University Innovation is a shareholder.
- AstraZenecastrategic partnerExclusively licensed sipavibart (AZD3152, now Kavigale) to AstraZeneca in May 2022. AstraZeneca advanced through SUPERNOVA Phase I/III clinical trial and obtained positive CHMP opinion for preexposure prophylaxis of COVID-19 in immunocompromised individuals aged 12 and older.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
RQ Bio competitors and assessment
Company assessmentDirect peers
- Vir Biotechnology: Vir Biotechnology develops monoclonal antibodies for serious infectious diseases including influenza (e.g., VIR-2482) and COVID-19, directly competing with RQ Bio in the LAAB space for viral prophylaxis in immunocompromised populations.
- Invivyd (formerly Adagio Therapeutics): Invivyd develops monoclonal antibodies for COVID-19 prevention (pemivibart), directly comparable to RQ Bio's sipavibart/Kavigale and RQB01 mechanism as passive-immunity LAABs targeting conserved viral epitopes.
Broad incumbents
- Regeneron Pharmaceuticals: Regeneron developed REGN-COV2 (casirivimab/imdevimab) for COVID-19 and operates a leading antibody platform with applications in infectious diseases, making it a broad incumbent comparable to RQ Bio's LAAB approach at much larger scale.
- Eli Lilly: Lilly developed bebtelovimab, a monoclonal antibody authorized for COVID-19 treatment, and operates a large antibody platform with infectious disease applications comparable to RQ Bio's LAAB programmes.
- GSK: GSK developed sotrovimab (Xevudy) for COVID-19 and is a major vaccine manufacturer, making it a broad incumbent whose mAb and vaccine franchises overlap with RQ Bio's prevention focus.
Others
- AstraZeneca: AstraZeneca is RQ Bio's licensing partner for Kavigale (sipavibart) and a strategic collaborator rather than direct competitor, but operates broadly in infectious disease biologics including COVID antibodies (Evusheld).
Emerging players
- AbCellera Biologics: AbCellera is an antibody discovery platform that partnered with Lilly on bebtelovimab and others, with similar technology overlap to RQ Bio's antibody discovery engine but a partnership-based business model.
- Modex Therapeutics: Modex develops antibody and peptide-based therapeutics for viral diseases including COVID-19, with similar modality focus to RQ Bio in passive-immunity prophylactics.
- Aridis Pharmaceuticals: Aridis develops monoclonal antibodies for infectious diseases including pneumonia and COVID, comparable to RQ Bio's LAAB platform approach for respiratory viral prophylaxis.
- Immunome: Immunome is an antibody discovery company developing therapeutics for infectious diseases and oncology, with technology overlap to RQ Bio's antibody platform and similar early-stage clinical positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
RQ Bio social profiles
Digital presenceRQ Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
RQ Bio leadership team
Management profileNumber of profiles
Profiles7 records
RQ Bio subsidiaries and ownership
Company hierarchySubsidiaries1 record
RQ Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
RQ Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about RQ Bio
What does RQ Bio do?
RQ Bio discovers and develops long-acting monoclonal antibody (LAAB) therapeutics that provide passive immunity against viral infections, with lead programme RQB01 designed to deliver once-yearly protection against seasonal influenza for immunocompromised and high-risk populations. The company also developed Kavigale (sipavibart), a monoclonal antibody for COVID-19 prevention in immunocompromised individuals aged 12 and older, which was exclusively licensed to AstraZeneca. RQ Bio's therapeutic antibodies target conserved epitopes of viral proteins via a dual mechanism of action to combine potent neutralising activity with resilience to seasonal variation.
Is RQ Bio a public or private company?
RQ Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was RQ Bio founded?
RQ Bio was founded in 2021. It employs 11 to 50 people.
Where is RQ Bio based?
RQ Bio is headquartered in London, United Kingdom, in the Europe region.
How does RQ Bio make money?
Two revenue lines are on record. Licensing Royalties are the primary driver. The others are future Product Revenue.
Who are RQ Bio's main competitors?
Direct peers on record are Vir Biotechnology and Invivyd (formerly Adagio Therapeutics). Broad incumbents are Regeneron Pharmaceuticals, Eli Lilly and GSK. AstraZeneca is listed as an others. Emerging players are AbCellera Biologics, Modex Therapeutics, Aridis Pharmaceuticals and Immunome.
Does RQ Bio have an API?
No public API is recorded for RQ Bio.
What industry is RQ Bio in?
RQ Bio's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAAEAH, Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins). Its NAICS code is 325414 and its SIC code is 2836.